Shares of California-based Allakos Inc. (NASDAQ:ALLK) rose 110.5% to a record close of $65.26 Monday amid a broader market plunge on positive phase II results with AK-002, its experimental therapy for people with two rare conditions, eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE).